◆英語タイトル:Memphasys Ltd (MEM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013364
◆発行会社(調査会社):
GlobalData
◆発行日:2017年11月28日
◆ページ数:27
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Memphasys Ltd (Memphasys), formerly Nusep Holdings Ltd is a life science company that develops and sells pre-cast electrophoresis gels, separations equipment and consumables, analytical software, and other biological products. The company offers gels which include tris glycine, and tris hepes. It offers buffers, stains and drying solutions. Memphasys offers proteomesep, which is a bench-top instrument capable of simultaneous charge and size separation of complex protein mixtures. The company also offers LA reagents and general reagents. It caters to therapeutic plasma, IVF clinical, and research consumables markets. The company operates in Australia, Singapore and the US. Memphasys is headquartered in Homebush West, New South Wales, Australia.
Memphasys Ltd (MEM) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Memphasys Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Memphasys Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Memphasys Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Memphasys Ltd, Medical Devices Deals, 2011 to YTD 2017 8
Memphasys Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Memphasys Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Private Equity 10
PrIME Biologics To Raise US$15.8 Million In Private Equity Financing 10
Equity Offering 11
Memphasys Plans to Raise USD0.3 Million in Rights Offering of Shares 11
Memphasys Plans to Raise USD0.9 Million in Private Placement of Shares 12
Memphasys Raises Funds in Public Offering of Shares 13
NuSep to Raise Funds through Share Purchase Plan 14
NuSep Completes Private Placement Of Shares For US$1 Million 15
NuSep Completes Rights Offering Of Shares For US$1.7 Million 16
NuSep Completes Public Offering Of Common Stock For US$1.9 Million 17
NuSep Completes Private Placement For US$0.99 Million 19
Debt Offering 21
Memphasys Plans to Raise USD0.2 Million in Public Offering of Notes Due 2017 21
Asset Transactions 22
Premier Biosoft Acquires ProteoIQ Business From NuSep 22
Acquisition 23
A-Bio Pharma To Acquire 10% Stake In PrIME Biologics From NuSep For US$4.8 Million 23
Memphasys Ltd – Key Competitors 24
Memphasys Ltd – Key Employees 25
Memphasys Ltd – Locations And Subsidiaries 26
Head Office 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27
List of Tables
Memphasys Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Memphasys Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 2
Memphasys Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Memphasys Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Memphasys Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Memphasys Ltd, Medical Devices Deals, 2011 to YTD 2017 8
Memphasys Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
PrIME Biologics To Raise US$15.8 Million In Private Equity Financing 10
Memphasys Plans to Raise USD0.3 Million in Rights Offering of Shares 11
Memphasys Plans to Raise USD0.9 Million in Private Placement of Shares 12
Memphasys Raises Funds in Public Offering of Shares 13
NuSep to Raise Funds through Share Purchase Plan 14
NuSep Completes Private Placement Of Shares For US$1 Million 15
NuSep Completes Rights Offering Of Shares For US$1.7 Million 16
NuSep Completes Public Offering Of Common Stock For US$1.9 Million 17
NuSep Completes Private Placement For US$0.99 Million 19
Memphasys Plans to Raise USD0.2 Million in Public Offering of Notes Due 2017 21
Premier Biosoft Acquires ProteoIQ Business From NuSep 22
A-Bio Pharma To Acquire 10% Stake In PrIME Biologics From NuSep For US$4.8 Million 23
Memphasys Ltd, Key Competitors 24
Memphasys Ltd, Key Employees 25